"
Mutation Status of KRAS, BRAF, PIK3CA and Expression Level of AREG and EREG Identify Responders to Cetuximab in a Large Panel of Patient Derived Colorectal Carcinoma Xenografts of All Four UICC Stages"
written by Paulina Pechańska, M. Becker, T. Mayr, B. Hinzmann, H.-P. Adams, I. Klaman, K.-H. Kretschmar, K. Kretschmar, K. Stecker, R. Mantke, R. Pauli, J. Pertschy, K. Hertel, K. Ridwelski, K. Hellwig, M. Pross, C. Radke, I. Fichtner, J. Hoffmann, A. Rosenthal,
published by
Journal of Cancer Therapy,
Vol.4 No.2, 2013
has been cited by the following article(s):
|
[1]
|
Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors
Nature Communications,
2017
DOI:10.1038/ncomms14262
|
|
|
|
|
[2]
|
Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors
Nature Communications,
2017
DOI:10.1038/ncomms14262
|
|
|
|
|
[3]
|
Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic review
Oncotarget,
2016
DOI:10.18632/oncotarget.11184
|
|
|
|
|
[4]
|
Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer
Molecular Cancer Therapeutics,
2014
DOI:10.1158/1535-7163.MCT-13-0753
|
|
|
|
|
[5]
|
Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
International Journal of Cancer,
2014
DOI:10.1002/ijc.28669
|
|
|
|